CBD delivery method approaches 100% bioavailability in dogs

A new CBD delivery method has achieved close to 100 per cent bioavailability in a clinical study on dogs.

The Israeli pharmaceutical tech company, Innocan has released results from a recent clinical study that evaluated the effectiveness of its CBD delivery system, known as Liposome Platform Technology (LPT), on dogs experiencing pain.

The study found that the injection of Innocan’s CBD delivery system into the subcutaneous fat under the skin could achieve a bioavailability level close to 100 per cent, according to a press release from the company.

Typically, oral administration of cannabidiol by humans results in bioavailability levels of between 6.5-20 per cent.

Bioavailability is the technical term for the amount of CBD that makes its way into the bloodstream. The low oral bioavailability of CBD in humans is a result of first-pass metabolism which ‘eats up’ the CBD before it can reach the bloodstream.

The research was conducted in collaboration with the Hebrew University of Jerusalem.

“One of the challenges with CBD treatments is its pharmacokinetic profile after oral administration that is characterised by low bioavailability and fast elimination,” said Professor Chezy Barenholz of The Hebrew University. 

“Our preliminary data show that we may overcome these major obstacles using the LPT technology and this is very encouraging.”

A liposomal delivery system is a drug preparation where the active ingredient, in this case CBD, is contained within tiny fat-like particles.

By administering injectable CBD encapsulated in liposomes, Innocan seeks to achieve long-lasting and therapeutic levels of CBD in the body. The company believes this will create a “far more effective” and prolonged therapeutic effect.

Innocan has carried out a series of experiments with its LPT platform on animals which have demonstrated initial positive results that demonstrate the delivery system’s prolonged release of CBD into the bloodstream with improved pharmacokinetic (PK) performance.

Innocan CEO, Iris Bincovich, commented: “It has been a long time coming, and now Innocan is showing remarkable findings from its CBD bioavailability trial using the LPT technology. We are optimistic about this being an important piece of information to both our shareholders and the scientific community.”

Innocan focuses on developing drug delivery platform technologies using cannabinoids to treat various conditions. The company is currently developing two drug delivery technologies, including the LPT CBD-loaded liposome platform. Research is in the preclinical trial phase for epilepsy and pain management.

• How to make the most of your CBD gummies
• Innocan’s CBD study shows promising results
• Medical cannabis experts Kanabo explain the different ways to consume CBD
• Making the case for medical cannabis vaping
• A study testing CBD on large animals shows positive results in blood tests